The growth inhibiting effect of docetaxel (Taxotere®) in head and neck squamous cell carcinoma xenografts
article
Docetaxel (Taxotere®) is a new antitumor agent with activity in patients with ovarian, lung and breast cancer. In this study, docetaxel was tested for its antitumor effect in human tumor xenografts derived from head and neck squamous cell carcinoma (HNSCC). A significant growth inhibiting effect was observed in the two tested lines, at the well tolerated dose of 20 m/kg docetaxel. Two intravenous injections were given with a week interval. Both lines were less sensitive to treatment with cisplatin, indicating that no cross-reactivity exists between these drugs. Docetaxel has a promising outlook in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Chemicals/CAS: Antineoplastic Agents, Phytogenic; Cisplatin, 15663-27-1; docetaxel, 114977-28-5; Paclitaxel, 33069-62-4
Topics
Antitumor effectDocetaxelHead and neck cancerSquamous cell carcinomaTaxolTaxotere®antineoplastic agentcisplatindocetaxelanimal experimentanimal modelarticlecancer inhibitioncell growthcontrolled studydrug cross reactivityfemalehead cancerintravenous drug administrationmouseneck cancernonhumanpriority journalsquamous cellsquamous cell carcinomatumor xenograftAnimalAntineoplastic Agents, PhytogenicCarcinoma, Squamous CellCell LineCisplatinComparative StudyFemaleHead and Neck NeoplasmsHumanMiceMice, NudeNeoplasm TransplantationPaclitaxelSupport, Non-U.S. Gov't
TNO Identifier
232638
ISSN
03043835
Source
Cancer Letters, 81(2), pp. 151-154.
Pages
151-154
Files
To receive the publication files, please send an e-mail request to TNO Repository.